A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China

NCT05732428 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer

Collaborators